Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 183   

Articles published

PFE 33.09 -0.20 (-0.60%)
price chart
Zacks Short Term Rating on Pfizer, Inc. (NYSE:PFE)
Research firm Zacks has rated Pfizer, Inc. (NYSE:PFE) and has ranked it at 3, indicating that for the short term the shares are a hold.
Shares of Pfizer, Inc. (NYSE:PFE) Sees Large Outflow of Money  OTC Outlook
Insider Buying: Pfizer Inc Purchases 714285 Shares of Pfizer Stock (PFE)  Dakota Financial News
Pfizer Raised Prices on 133 Drugs This Year, And It's Not Alone
Pfizer Inc., the nation's biggest drugmaker, has raised prices on 133 of its brand-name products in the U.S. this year, according to research from UBS, more than three-quarters of which added up to hikes of 10 percent or more.
Pfizer Inc. Announces Final Results of Exchange Offers
NEW YORK, Oct 02, 2015 (BUSINESS WIRE) -- Pfizer Inc. (“Pfizer”) PFE, +3.89% announced today the final results of its previously announced offers to exchange any and all validly tendered and accepted notes of each series listed in the table below ...
Watch List -Pfizer (PFE), Anworth Mortgage Asset (ANH), XenoPort (XNPT ...  Investor Wired
Large Outflow of Money Witnessed in Pfizer, Inc.
Shares of Pfizer, Inc. (NYSE:PFE) traded 0.06 points or 0.18% higher at $33.54.The total intraday money flow for the shares came in at a disappointing $(-20.04) million.
BIND Therapeutics Announces Pfizer Inc. Exercises Option to Advance ...
CAMBRIDGE, Mass., Sep 24, 2015 (BUSINESS WIRE) -- BIND Therapeutics, Inc. BIND, -0.67% a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today announced that Pfizer Inc. exercised its ...
BIND Therapeutics Announces Pfizer Obtains License for Drug  Pharmaceutical Processing
Pfizer to develop cancer drug partnered with Cambridge biotech Bind  Boston Business Journal (blog)
Pfizer Inc, Merck and Co. Also To Blame For US Drug Price Hikes
An exorbitant price hike by a small, obscure biotech, Turing Pharmaceutical, triggered a massive political debate on specialty pharma drug pricing in the last week of September.
Eli Lilly and Co (LLY) Breast Cancer Drug May Challenge Pfizer Inc. Ibrance
Eli Lilly and Co (NYSE:LLY) on Thursday received Breakthrough Therapy status for its breast cancer drug candidate, abemaciclib, from the Food and Drug Administration (FDA).
Pfizer, Inc. (NYSE:PFE) Handed a Crowd Sourced Rating of 3.75
Shares of Pfizer, Inc. (NYSE:PFE) have been given an average rating of 3.75 according to Closing Bell compiles crowd-sourced stock ratings provided by independent analysts, investors, traders and students.
Pfizer Edges Outlook Higher to Factor in Hospira
Pfizer acquired smaller rival Hospira in a $16 billion deal that closed earlier this month. The acquisition is expected to transform the pharmaceutical company into a leading player in the emerging market for lower-priced knockoffs of costly biotech drugs.
Pfizer lifts outlook to factor in Hospira purchase  MarketWatch
Pfizer (PFE) Boosts FY15 Outlook Following Completion of Hospira Acquisition
Company Shares of Pfizer, Inc. (NYSE:PFE) Rally 3.73%
Shares of Pfizer, Inc. (NYSE:PFE) rose by 3.73% in the past week and 5.45% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 2.67% and the outperformance increases to 3.82% for the last 4 weeks.
Drug Manufacturer Most Active- Pfizer Inc. (NYSE:PFE), Merck & Co. Inc ...  StreetWise Report (press release)
Hot Healthcare Stocks: Pfizer Inc. (NYSE:PFE), Merck & Co. Inc. (NYSE ...  Benchmark Monitor